Novo Nordisk Seeks Approval of Sickle Cell Disease Drug

MT Newswires Live11-13

Novo Nordisk (NVO) said Friday it submitted etavopivat, a once-daily oral treatment for sickle cell disease in patients 12 and older, for approval with the US Food and Drug Administration and the European Medicines Agency.

A phase 3 trial showed the drug cut vaso-occlusive crises by 27% and delayed the first crisis by about four months versus placebo, the company said.

The FDA and European regulators are expected to decide on the applications in 2027, and etavopivat holds orphan and fast track designations, Novo Nordisk said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment